Ana Cabranes

Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis

Ana Cabranes, Kateřina Venderová, Eva de Lago et al. · Neurobiology of Disease · 2005 · 133 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake

Eva de Lago, Alessia Ligresti, Giorgio Ortar et al. · European Journal of Pharmacology · 2003 · 97 citations

Medicine, Medicinal Chemistry, Pharmacology +5

Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects

Eva de Lago, Miguel Moreno‐Martet, Ana Cabranes et al. · Neuropharmacology · 2012 · 78 citations

Life Sciences, Neuroscience, Pharmacology +16

UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders

Eva de Lago, Javier Fernández‐Ruíz, Silvia Ortega‐Gutiérrez et al. · European Neuropsychopharmacology · 2005 · 76 citations

Medicine, Neurology, Pharmacology +16

Changes in cannabinoid CB₁ receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis

Fernando Berrendero, Antonio Sánchez, Ana Cabranes et al. · Synapse · 2001 · 66 citations

Life Sciences, Neurology, Neuroscience +17